PTGDS overexpression was found to reverse the regulatory effects of Erastin and Sorafenib on the accumulation of lipid ROS (Fig. 5g, h) and cell proliferation (Fig. 5i) in PTCL cells. This evidence concerns the gene PTGDS and mature T-cell and NK-cell non-Hodgkin lymphoma.